{"Clinical Trial ID": "NCT02924883", "Intervention": ["INTERVENTION 1:", "Trastuzumab Emtansine + Placebo", "placebo corresponds to atezolizumab, followed by trastuzumab emtansine 3.6 mg/kg IV by infusion on day 1 of cycle 1 and later on day 1 of each 21-day cycle until disease progression, toxicity not manageable or end of study by the sponsor (up to a study duration of approximately 40 months)", "INTERVENTION 2:", "- Trastuzumab Emtansine + Atezolizumab", "Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) IV infusion on day 1 of cycle 1 and thereafter on day 1 of each 21-day cycle until disease progression, toxicity impossible to manage or end of study by the sponsor (up to a study duration of approximately 40 months)"], "Eligibility": ["Incorporation criteria:", "Samples of archive tumours should be obtained from primary and/or metastatic sites.", "\u2022 Capable of submitting tumour tissues that are evaluable for programmed expression ligand 1 (PD-L1)", "\u00b7 HER-2 positive BC as defined by an immunohistochemical score of 3 or a gene amplified by in situ hybridization as defined by a ratio greater than or equal to (>=) 2.0 for the number of copies of HER2 genes to the number of chromosomes 17 copies", "Invasive B.C. confirmed histologically or cytologically: incurable, non-resectable, locally advanced B.C. previously treated by multimodality or metastatic B.C.", "Previous treatment for B.C. in adjuvant; locally advanced non-resectable treatment; or metastatic parameters; which should include both taxane and trastuzumab (only or in combination with another agent)", "A progression should have taken place during or after the most recent treatment for B.C. locally advanced/metastatic or within 6 months of the end of the adjuvant treatment.", "- Participants must have a measurable disease that is assessable according to RECIST v1.1", "Eastern Cooperative Oncology Group Performance Status of 0 or 1", "Negative serum pregnancy test within 7 days of registration in premenopausal women and women less than 12 months after onset of menopause", "Use of a highly effective contraceptive method as defined by the protocol", "- Exclusion criteria:", "\u2022 Prior treatment with trastuzumab emtansine, a differentiation group 137 agonists, an anti-mortem-1 therapeutic antibody or an anti-PD-L1 antibody or route targeting agents", "Receipt of any anticancer/biological or experimental treatment within 21 days prior to cycle 1 Day 1, with the exception of hormone therapy, which may be given up to 7 days prior to cycle 1 Day 1; recovery of treatment-related toxicity according to other eligibility criteria", "Radiotherapy within 2 weeks prior to cycle 1, Day 1", "A history of exposure to cumulative doses of anthracyclines", "\u2022 History of other malignancies over the past 5 years, except for carcinomas appropriately treated in situ for cervix, non-melanoma skin carcinoma, stage I uterus cancer or participants who have undergone potentially curative treatment without evidence of disease and who are considered by the treating physician to be at low risk of recurrence", "Cardiopulmonary dysfunction, symptomatic pleural effusion, pericardial effusion or ascitis", "Participants with severe infection within 4 weeks prior to randomization, including, but not limited to, hospitalization for complications of infection, bacteraemia or severe pneumonia", "A serious and uncontrolled systemic disease", "\u2022 Major surgery or significant traumatic injury within 28 days prior to randomization or anticipation of major surgery during study treatment", "Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, autoimmune liver disorders, sclerosis cholangitis or active infection with human immunodeficiency virus, hepatitis B virus or hepatitis C virus", "Need for current chronic corticosteroid treatment (>=10 mg prednisone per day or equivalent dose of other anti-inflammatory corticosteroids)", "The compression of the spinal cord was not permanently treated with surgery and/or radiation, or the compression of the spinal cord previously diagnosed and treated without evidence that the disease was clinically stable for more than (>) 2 weeks prior to randomization", "Participants with known central nervous system disease", "Nervous system disorders", "\u2022 History of autoimmune disease", "\u00b7 Pre-transplantation of allogeneic stem cells or solid organs", "Active tuberculosis", "The receipt of a live attenuated vaccine within 4 weeks of randomization or anticipation of such a live attenuated vaccine will be required during the study.", "- Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the medicinal product (regardless of the shortest) prior to randomisation", "Treatment with systemic corticosteroids or other systemic immunosuppressive medicinal products within 2 weeks prior to randomisation, or anticipated need for systemic immunosuppressive medicinal products during trial", "Participants who are breast-feeding or intend to become pregnant during the study"], "Results": ["Performance measures:", "The progression-free survival (PFS) determined by the investigator's evaluation of tumours using the criteria for assessing responses in solid tumours (RECIST) Version 1.1 (v1.1)", "The progression was defined as an increase of at least 20% in the sum of the diameters of the target lesions with an absolute increase of at least 5 mm (mm) or the occurrence of one or more new lesions.", "Time frame: Baseline up to about 15 months", "Results 1:", "Title of the arm/group: Trastuzumab Emtansine + Placebo", "Description of the arm/group: Placebo corresponding to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on the first day of cycle 1 and thereafter on the first day of each 21-day cycle until disease progression, toxicity impossible to manage or end of study by the sponsor (until study duration of approximately 40 months)", "Total number of participants analysed: 69", "Median (95% confidence interval)", "Unit of measure: month 6.8 (4.0-11.1)", "Results 2:", "Title of the arm/group: Trastuzumab Emtansine + Atezolizumab", "Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) IV infusion on day 1 of cycle 1 and day 1 of each 21-day cycle until disease progression, toxicity not manageable or end of study by the sponsor (up to a study duration of approximately 40 months)", "Total number of participants analysed: 133", "Median (95% confidence interval)", "Unit of measure: month 8.2 (5.8-10.7)"], "Adverse Events": ["Undesirable Events 1:", "Total: 52/133 (39.10 per cent)", "Thrombocytopenia 2/133 (1.50%)", "Anemia 1/133 (0.75%)", "Disseminate intravascular coagulation 0.133 (0.00 %)", "Atrial thrombosis 1/133 (0.75%)", "- Heart failure 0/133 (0.00 %)", "Vertigo 0/133 (0.00 %)", "- Vomiting 3/133 (2.26 per cent)", "Nausea 1/133 (0.75%)", "- Collision 1/133 (0.75%)", "1/133 (0.75%)", "Enterite 0/133 (0.00 %)", "Abdominal pain 0.133 (0.00 %)", "Adverse Events 2:", "Total: 16/67 (23.88%)", "Thrombocytopenia 0/67 (0.00 %)", "Anemia 0/67 (0.00 %)", "Disseminate intravascular coagulation 1/67 (1.49 %)", "Atrial thrombosis 0/67 (0.00 %)", "Heart failure 1/67 (1.49%)", "Vertigo 1/67 (1.49%)", "Vomiting 0/67 (0.00 %)", "Nausea 1/67 (1.49%)", "- Collision 0/67 (0.00 %)", "Constipation 0/67 (0.00 %)", "Enterite 1/67 (1.49%)", "Abdominal pain 2/67 (2.99 per cent)"]}